Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
CMTA Board of Directors
…as leading the charge for development of treatments. Bernard Coulie Bernard is the CEO and President of Pliant Therapeutics, a NASDAQ-listed biopharmaceutical company focused on developing novel treatments for rare…
CMTA-STAR Biotech & Alliance Partners
…endpoints to track treatment effects to be used in a planned gene therapy trial. Read more Frontage Laboratories Frontage Laboratories, Inc. is a global pharmaceutical development organization (PDO) advancing drug…
Nervosave: Shaping the Future of Genetic Therapy for CMT1A
…their condition and feelings toward this type of treatment. Why Participate in the Nervosave Survey? By participating in this survey, you contribute to research that could influence the future of…
Pharnext Announces Disappointing Results for CMT1A Drug Trial PXT-3003
…can be influenced by placebo and training effects, making it difficult to determine the impact of treatment. In particular, the company said, the Overall Neuropathy Limitation Scale (ONLS), which measures…
Actio Biosciences Doses First Participant in Phase I Clinical Trial | Future Phase Ib Clinical Trial to Focus on CMT2C
…complex form of CMT that presents significant challenges for patients and their families. We proudly support Actio Biosciences in advancing this potential treatment.” The Phase I study is a randomized,…
CMTA Fuels Breakthrough Imaging Research to Address CMT2A’s Cellular Weakness
…Accelerate Research (CMTA-STAR) project will equip scientists with tools to accelerate the development of potential treatments for CMT2A and other axonal forms of CMT. Investigating CMT2A at the Cellular Level…
CMTA’s $300K Investment in CRISPR for CMT2A
…Current research suggests that silencing (turning off) only the mutated copy could restore peripheral nerve health, making gene editing an encouraging approach for treatment. Led by Bruce Conklin, MD, CMTA-STAR…
Accelerating Genetic Therapy for CMT4B1: A CMTA Research Update
…research for CMT4B1 is a critical step toward expanding treatment possibilities for the broader CMT community,” said Katherine Forsey, PhD, CMTA’s Chief Research Officer. “Through CMTA-STAR, we are not only…
CMTA-STAR Clinical Expert Board Co-Chair Prof. Mary Reilly Honored with Prestigious MBE
…diagnosis, and treatment of Charcot-Marie-Tooth disease (CMT). As Co-Chair of CMTA-STAR’s Clinical Expert Board (CEB), she has played a vital role in shaping research strategies, accelerating therapeutic development, and improving…